Ask AI
ProCE Banner Activity

From the Conference to the Clinic: Applying New Data From EACS 2025 to HIV Care in Europe

Clinical Thought

Hepatitis B virus coinfection and weight gain while on antiretroviral therapy are key concerns for people living with HIV in Europe, where both these chronic conditions are prevalent. Learn how new data from EACS 2025 can help inform how you address these concerns in your clinical practice.

Released: December 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

Disclosure

Primary Author

Karine Lacombe, MD, PhD: consultant/advisor/speaker: Gilead, GSK, Merck Sharp & Dohme, ViiV.